Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Parkinson Disease, Secondary”

138 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 138 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06483334
What this trial is testing

Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Who this might be right for
Metastatic Urothelial CarcinomaLocally Advanced Urothelial Carcinoma
Merck Sharp & Dohme LLC 38
Early research (Phase 1)Study completedNCT05017012
What this trial is testing

Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)

Who this might be right for
Advanced or Metastatic Solid Tumors
Merck Sharp & Dohme LLC 142
Testing effectiveness (Phase 2)Active Not RecruitingNCT05608044
What this trial is testing

Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Agenus Inc. 234
Large-scale testing (Phase 3)Study completedNCT03834506
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Who this might be right for
Prostatic Neoplasms
Merck Sharp & Dohme LLC 1,030
Early research (Phase 1)Ended earlyNCT04135352
What this trial is testing

Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

Who this might be right for
Neoplasm Metastasis
Merck Sharp & Dohme LLC 35
Early research (Phase 1)Study completedNCT01295827
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)

Who this might be right for
Cancer, Solid Tumor
Merck Sharp & Dohme LLC 1,260
Large-scale testing (Phase 3)Study completedNCT03950674
What this trial is testing

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Who this might be right for
Non-Small-Cell Lung Carcinoma
Merck Sharp & Dohme LLC 40
Testing effectiveness (Phase 2)Study completedNCT06671938
What this trial is testing

Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy

Who this might be right for
Parkinson DiseaseMultiple System Atrophy
BioArctic AB 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT04626479
What this trial is testing

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 400
Large-scale testing (Phase 3)Study completedNCT02252042
What this trial is testing

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Who this might be right for
Head and Neck Squamous Cell Cancer
Merck Sharp & Dohme LLC 495
Large-scale testing (Phase 3)Study completedNCT04934722
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 186
Not applicableStudy completedNCT06281314
What this trial is testing

The Efficacy of VESPA 2.0 for Cognitive Rehabilitation in Patients With Mild Cognitive Impairment

Who this might be right for
Neurodegenerative DiseasesCognitive DeclineParkinson Disease Dementia+2 more
IRCCS Centro Neurolesi Bonino Pulejo 60
Not applicableLooking for participantsNCT04179695
What this trial is testing

Evaluation of a New Communication Aid Tool to Favor Global Patient Centered Care

Who this might be right for
Parkinson's Disease
University Hospital, Lille 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT04995523
What this trial is testing

AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Who this might be right for
Non-Small-Cell Lung Carcinoma
AstraZeneca 212
Early research (Phase 1)Study completedNCT03010176
What this trial is testing

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Who this might be right for
Solid TumorsLymphoma
Merck Sharp & Dohme LLC 156
Testing effectiveness (Phase 2)Study completedNCT04704219
What this trial is testing

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 160
Early research (Phase 1)Study completedNCT06460961
What this trial is testing

MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

Who this might be right for
Neoplasm Metastasis
Merck Sharp & Dohme LLC 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04626518
What this trial is testing

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 370
Large-scale testing (Phase 3)Study completedNCT03358472
What this trial is testing

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Who this might be right for
Head and Neck Cancer
Incyte Corporation 89
Testing effectiveness (Phase 2)Study completedNCT04116073
What this trial is testing

INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

Who this might be right for
Pancreatic Cancer Non-resectablePancreatic Cancer Metastatic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 25
Next Page